Remove Ads

Welcome, Guest
You have to register before you can post on our site.

Username
  

Password
  





Search Forums

(Advanced Search)

Forum Statistics
» Members: 8
» Latest member: dvicelulares
» Forum threads: 42
» Forum posts: 62

Full Statistics

Online Users
There are currently 0 online users.
» 0 Member(s) | 0 Guest(s)

Latest Threads
The FDA Has Officially Ap...
Forum: World Drug Market News
Last Post: sonusood
10-08-2022, 04:41 PM
» Replies: 1
» Views: 96
The Covid Threat Is Here ...
Forum: World Drug Market News
Last Post: sonusood
10-08-2022, 04:12 PM
» Replies: 1
» Views: 100
Ultra-Vaxxed Israel’s Cri...
Forum: World Drug Market News
Last Post: sonusood
10-08-2022, 03:43 PM
» Replies: 1
» Views: 98
FDA grants full approval ...
Forum: World Drug Market News
Last Post: sonusood
10-08-2022, 02:56 PM
» Replies: 1
» Views: 98
COVID-19 Booster Shots ea...
Forum: Jobs, Partnerships and Passive Income Opportunities.
Last Post: sonusood
10-08-2022, 02:25 PM
» Replies: 1
» Views: 102
Caregivers, Nanny, Practi...
Forum: Jobs, Partnerships and Passive Income Opportunities.
Last Post: sonusood
10-08-2022, 01:48 PM
» Replies: 2
» Views: 117
What you need to know abo...
Forum: World Drug Market News
Last Post: sonusood
10-08-2022, 12:51 PM
» Replies: 2
» Views: 98
The 7 Best Places to Buy ...
Forum: Buy and Sell Health Marketplace
Last Post: sonusood
10-08-2022, 11:51 AM
» Replies: 3
» Views: 83
Guide To Selling Health P...
Forum: Jobs, Partnerships and Passive Income Opportunities.
Last Post: sonusood
10-08-2022, 10:43 AM
» Replies: 3
» Views: 112
Covid Rapid Test Kits To ...
Forum: Buy and Sell Health Marketplace
Last Post: sonusood
10-08-2022, 08:03 AM
» Replies: 3
» Views: 71

 
  Big Pharma World Drug Market earn $500 - $1,500 per day Autopilot
Posted by: admin - 08-14-2021, 03:18 PM - Forum: Jobs, Partnerships and Passive Income Opportunities. - No Replies

Healthcare & Pharmaceuticals
Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market
COVID-19 vaccine market booms; Pfizer, Moderna to gain billions
Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market


NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

[Image: beautiful-woman-working-online-laptop-wh...8-5329.jpg]

For several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.

Now a growing list of governments, including Chile, Germany and Israel, have decided to offer booster doses to older citizens or people with weak immune systems in the face of the fast-spreading Delta variant.

Send an email to:  dreamfundingworld@gmail.com

[Image: ool-1.jpg]

World Drug Market
Become a partner and earn $500 - $1,500 per day. (Limited space)
Share your dream business idea. Get sponsored today and receive up to $350,000 in funding.
Reply to emails and ad-posting jobs also available .  US$150 per day + bonus.

https://stayintoronto.createmybb4.com/thread-554.html
https://covid19vaccinejobs.blogspot.com/...-earn.html
https://covid19boostershots.blogspot.com...-1500.html
https://coronavirusboostershots.blogspot...hecks.html
https://vancouverhealth.createmybb4.com/thread-16.html
https://vancouverhealth.blogspot.com/202...-work.html
https://worldpropertyinvestments.blogspo...50000.html

Thanks

Print this item

  Drug firms poised to make billions of dollars from Covid booster jabs
Posted by: admin - 08-14-2021, 03:12 PM - Forum: World Drug Market News - No Replies

[Image: 3500.jpg?width=620&quality=85&auto=forma...9c3c2a78e4]
[*]The drug companies Pfizer, BioNTech and Moderna are poised to make billions of dollars from Covid-19 booster jabs this autumn, with analysts estimating that sales could rival the $6bn-a-year market for seasonal flu vaccines.
The UK government is expected to announce details of its booster programme in the coming days, based on formal advice from the Joint Committee on Vaccination and Immunisation, but the health secretary, Sajid Javid, has suggested the over-50s could be offered a dose along with their winter flu jabs.

The UK is expected to join France and Germany in offering follow-up doses from September. The US authorities on Friday approved a third dose for those with compromised immune systems, and Israel and Chile have begun administering boosters to their elderly citizens.
Advertisement

However, health experts are warning that many more people around the world will die of Covid if western countries prioritise boosters for their own populations instead of sharing them with the rest of the world.
Moderna, Pfizer and its German partner BioNTech have already inked more than $72bn (£52bn) in sales for this year alone, in deals for supplying follow-up shots and also the initial two doses for those being inoculated for the first time in less wealthy countries.
Analysts polled by data group Refinitiv have forecast revenue of more than $6.6bn for the Pfizer/BioNTech shot and $7.6bn for Moderna in 2023, mostly from booster sales. They expect the annual market to settle at about $5bn or higher eventually, with additional drugmakers competing for those sales.
They are likely to include Maryland-based Novavax, which has just struck a deal with the EU to supply up to 200m doses of its vaccine, which is yet to be approved by the EU’s drugs regulator. France’s Sanofi and the UK drugmaker GSK are also working on a vaccine, which they hope will be ready by the end of the year.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk
Britain’s AstraZeneca and the US firm Johnson & Johnson are collecting more data on boosters of their vaccines. New jabs from Novavax, Sanofi and Germany’s CureVac could also be used as boosters, assuming they are approved by regulators.
Damien Conover, a healthcare analyst at Morningstar, said: “A lot of these firms aren’t even in the market yet. I think within a year’s time, all these companies will have booster strategies.”
The jabs have allowed a return to a more normal life in western countries, but have also hugely benefited their makers.
The market value of Nasdaq-listed BioNTech, which was a small German drug developer before the pandemic, has soared to $92bn, catapulting it into the top 10 most valuable German companies, while Massachusetts-based Moderna has made its first profit ever on the back of its vaccine.
Vaccine makers argue that booster shots are needed due to evidence of waning antibody levels after six months and rising infection rates in countries hit by the Delta variant.
But the programmes are controversial. The World Health Organization has called a halt to all boosters until the end of September, saying supplies should be safeguarded for poorer countries that have yet to inoculate significant numbers of citizens.
Prof Sir Andrew Pollard, the head of the Oxford vaccine group, and Seth Berkley, the chief executive of Gavi, the vaccine alliance, describe this as “a key moment for decision-makers”.
“Large-scale boosting in one rich country would send a signal around the world that boosters are needed everywhere,” they write in the Guardian. “This will suck many vaccine doses out of the system, and many more people will die because they never even had a chance to get a single dose.”

… we have a small favour to ask. Millions are turning to the Guardian for open, independent, quality news every day, and readers in 180 countries around the world now support us financially.
We believe everyone deserves access to information that’s grounded in science and truth, and analysis rooted in authority and integrity. That’s why we made a different choice: to keep our reporting open for all readers, regardless of where they live or what they can afford to pay. This means more people can be better informed, united, and inspired to take meaningful action.
In these perilous times, a truth-seeking global news organisation like the Guardian is essential. We have no shareholders or billionaire owner, meaning our journalism is free from commercial and political influence – this makes us different. When it’s never been more important, our independence allows us to fearlessly investigate, challenge and expose those in power. Support the Guardian from as little as $1 – it only takes a minute. If you can, please consider supporting us with a regular amount each month. Thank you.

Print this item